Throughout the last three months, 24 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $1194.29, a high estimate of $1300.00, and a low estimate of $1000.00. Surpassing the previous average price target of $1151.54, the current average has increased by…